Wedbush raised the firm’s price target on Neurocrine (NBIX) to $166 from $151 and keeps an Outperform rating on the shares. The firm notes the company reached an agreement to acquire Soleno Therapeutics (SLNO) for $2.9B. While Vykat was not on Wedbush’s radar as a potential target for Neurocrine, the firm does think the Prader-Willi Syndrome makes sense for Neurocrine’s current infrastructure.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $199 from $190 at BofA
- Balanced Risk-Reward After Soleno Acquisition Supports Neutral Stance on Neurocrine
- Neurocrine price target raised to $215 from $192 at H.C. Wainwright
- Neurocrine price target raised to $166 from $151 at Baird
- Neurocrine price target raised to $242 from $204 at Citi